Cargando…
Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
(1) Introduction: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with hematologic malignancies (HM) and stem cell transplants (SCT). Isavuconazole was approved by FDA as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779319/ https://www.ncbi.nlm.nih.gov/pubmed/35050014 http://dx.doi.org/10.3390/jof8010074 |
_version_ | 1784637546718822400 |
---|---|
author | Dagher, Hiba Hachem, Ray Chaftari, Anne-Marie Jiang, Ying Ali, Shahnoor Deeba, Rita Shah, Shivan Raad, Issam |
author_facet | Dagher, Hiba Hachem, Ray Chaftari, Anne-Marie Jiang, Ying Ali, Shahnoor Deeba, Rita Shah, Shivan Raad, Issam |
author_sort | Dagher, Hiba |
collection | PubMed |
description | (1) Introduction: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with hematologic malignancies (HM) and stem cell transplants (SCT). Isavuconazole was approved by FDA as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosis. The aim of this study is to look at the real-world use of Isavuconazole in patients with HM and evaluate their clinical outcomes and safety. (2) Methods: We conducted a retrospective study of HM patients at MD Anderson Cancer Center who had definite, probable or possible mold infections between 1 April 2016 and 31 January 2020 and were treated with Isavuconazole for a period of at least 7 days. Clinical and radiological findings were assessed at baseline and at 6 and 12 weeks of follow up. (3) Results: We included 200 HM patients with IFIs that were classified as definite (11), probable (63) and possible (126). Aspergillus spp was the most commonly isolated pathogen. The majority of patients (59%) received prophylaxis with anti-mold therapy and Isavuconazole was used as a primary therapy in 43% of patients, and as salvage therapy in 58%. The switch to Isavuconazole was driven by the failure of the primary therapy in 66% of the cases and by adverse effects in 29%. Isavuconazole was used as monotherapy in 30% of the cases and in combination in 70%. Adverse events possibly related to Isavuconazole were reported in eight patients (4%) leading to drug discontinuation. Moreover, a favorable response with Isavuconazole was observed in 40% at 6 weeks and in 60% at 12 weeks. There was no significant difference between isavuconazole monotherapy and combination therapy (p = 0.16 at 6 weeks and p = 0.06 at 12 weeks). Finally, there was no significant difference in outcome when Isavuconazole was used after failure of other anti-mold prophylaxis or treatment versus when used de novo as an anti-mold therapy (p = 0.68 at 6 weeks and p = 0.25 at 12 weeks). (4) Conclusions: Whether used as first-line therapy or after the failure of other azole and non-azole prophylaxis or therapies, isavuconazole seems to have a promising clinical response and a good safety profile as an antifungal therapy in high-risk cancer patients with hematologic malignancies. Moreover, combination therapy did not improve the outcome compared to Isavuconazole therapy. |
format | Online Article Text |
id | pubmed-8779319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87793192022-01-22 Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant Dagher, Hiba Hachem, Ray Chaftari, Anne-Marie Jiang, Ying Ali, Shahnoor Deeba, Rita Shah, Shivan Raad, Issam J Fungi (Basel) Article (1) Introduction: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with hematologic malignancies (HM) and stem cell transplants (SCT). Isavuconazole was approved by FDA as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosis. The aim of this study is to look at the real-world use of Isavuconazole in patients with HM and evaluate their clinical outcomes and safety. (2) Methods: We conducted a retrospective study of HM patients at MD Anderson Cancer Center who had definite, probable or possible mold infections between 1 April 2016 and 31 January 2020 and were treated with Isavuconazole for a period of at least 7 days. Clinical and radiological findings were assessed at baseline and at 6 and 12 weeks of follow up. (3) Results: We included 200 HM patients with IFIs that were classified as definite (11), probable (63) and possible (126). Aspergillus spp was the most commonly isolated pathogen. The majority of patients (59%) received prophylaxis with anti-mold therapy and Isavuconazole was used as a primary therapy in 43% of patients, and as salvage therapy in 58%. The switch to Isavuconazole was driven by the failure of the primary therapy in 66% of the cases and by adverse effects in 29%. Isavuconazole was used as monotherapy in 30% of the cases and in combination in 70%. Adverse events possibly related to Isavuconazole were reported in eight patients (4%) leading to drug discontinuation. Moreover, a favorable response with Isavuconazole was observed in 40% at 6 weeks and in 60% at 12 weeks. There was no significant difference between isavuconazole monotherapy and combination therapy (p = 0.16 at 6 weeks and p = 0.06 at 12 weeks). Finally, there was no significant difference in outcome when Isavuconazole was used after failure of other anti-mold prophylaxis or treatment versus when used de novo as an anti-mold therapy (p = 0.68 at 6 weeks and p = 0.25 at 12 weeks). (4) Conclusions: Whether used as first-line therapy or after the failure of other azole and non-azole prophylaxis or therapies, isavuconazole seems to have a promising clinical response and a good safety profile as an antifungal therapy in high-risk cancer patients with hematologic malignancies. Moreover, combination therapy did not improve the outcome compared to Isavuconazole therapy. MDPI 2022-01-13 /pmc/articles/PMC8779319/ /pubmed/35050014 http://dx.doi.org/10.3390/jof8010074 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dagher, Hiba Hachem, Ray Chaftari, Anne-Marie Jiang, Ying Ali, Shahnoor Deeba, Rita Shah, Shivan Raad, Issam Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title | Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title_full | Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title_fullStr | Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title_full_unstemmed | Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title_short | Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant |
title_sort | real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779319/ https://www.ncbi.nlm.nih.gov/pubmed/35050014 http://dx.doi.org/10.3390/jof8010074 |
work_keys_str_mv | AT dagherhiba realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT hachemray realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT chaftariannemarie realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT jiangying realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT alishahnoor realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT deebarita realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT shahshivan realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant AT raadissam realworlduseofisavuconazoleasprimarytherapyforinvasivefungalinfectionsinhighriskpatientswithhematologicmalignancyorstemcelltransplant |